Thinking of joining a study?

Register your interest

Become a volunteer?

Clinical trials for Cancer in United States

7944 results

Sort By:

A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers

Study ID: NCT06243757
Start Date: 2024-01-08
End Date: 2036-01-08
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

10

Intervention / Treatment

MDASI-GI

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors

Study ID: NCT05592626
Start Date: 2023-01-04
End Date: 2026-10
Study Type

Interventional

Study Phase

Phase2

No. of Participants

365

Intervention / Treatment

Star ౦౬౦౨

Sponsor

Marengo Therapeutics, Inc.

Source: clinicaltrials.gov

Share:
Add to list

A Study of Enfortumab Vedotin in People with Urothelial Carcinoma of the Upper Urinary Tract

Study ID: NCT05868265
Start Date: 2023-06-02
End Date: 2025-05
Study Type

Interventional

Study Phase

Phase2

No. of Participants

24

Intervention / Treatment

Emportumab Vedotin

Radical surgery

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

Study ID: NCT04223765
Start Date: 2020-11-12
End Date: 2043-03-22
Study Type

Interventional

Study Phase

Phase1

No. of Participants

20

Intervention / Treatment

CAR.k.28

Fludarabine

Cyclophosphamide

Bendemustine

Sponsor

UNC Lineberger Comprehensive Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Study ID: NCT06790966
Start Date: 2025-04
End Date: 2029-02
Study Type

Interventional

Study Phase

Phase3

No. of Participants

351

Intervention / Treatment

Combination Treatment of PDS0101 and Pembrolizumab

Pembrolizumab Monotherapy

Sponsor

PDS Biotechnology Corp.

Source: clinicaltrials.gov

Share:
Add to list

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial

Study ID: NCT06378866
Start Date: 2024-06-03
End Date: 2029-05-31
Study Type

Interventional

Study Phase

Phase2

No. of Participants

120

Intervention / Treatment

Abiraterone

Apalutami

Biospecimen Collection

Bone Scan

Computed Tomography

Darolutami

Degarelix

Enzalutamid

Goserelin

Histrelin

Leuprolide

Magnetic Resonance Imaging

Patient Observation

Positron Emission Tomography

Prednisone

Administration questionnaire

Relugolix

Stereotactic Body Radiation Therapy

Triptorelin

Sponsor

Mayo Clinic

Source: clinicaltrials.gov

Share:
Add to list

Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

Study ID: NCT05379166
Start Date: 2022-06-23
End Date: 2025-07-15
Study Type

Interventional

Study Phase

Phase2

No. of Participants

53

Intervention / Treatment

Azacitidine

Quality-of-Life Assessment

Administration questionnaire

Venetoclax

Sponsor

A borate

Source: clinicaltrials.gov

Share:
Add to list

Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

Study ID: NCT00579566
Start Date: 2002-06
End Date: 2025-06
Study Type

Observational

Study Phase

Not Applicable

No. of Participants

3000

Intervention / Treatment

Specimen protocol

Sponsor

Memorial Sloan Kettering Cancer Center

Source: clinicaltrials.gov

Share:
Add to list

A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients with Hematological Malignancies

Study ID: NCT04937166
Start Date: 2022-01-13
End Date: 2025-06
Study Type

Interventional

Study Phase

Phase1

No. of Participants

36

Intervention / Treatment

DSP107

Azacitidine

Venetoclax

Sponsor

Havoc medical

Source: clinicaltrials.gov

Share:
Add to list

Natural Progesterone for the Treatment of Recurrent Glioblastoma

Study ID: NCT05091866
Start Date: 2022-04-11
End Date: 2026-08-25
Study Type

Interventional

Study Phase

Early_phase1

No. of Participants

32

Intervention / Treatment

Quality-of-Life Assessment

Administration questionnaire

Therapeutic Progesterone

Sponsor

Emory University

Source: clinicaltrials.gov

Share:
Add to list